Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Healthcare-Associated Pneumonia Pathogens Testing Has Limited Success

By LabMedica International staff writers
Posted on 05 Oct 2009
Testing for pathogens in patients with healthcare-associated pneumonia (HCAP) provides results in less than one-third of cases, according to recent preliminary findings.

In a six-year retrospective study, a pathogen was isolated from 31% of samples taken from nearly 1,600 patients with HCAP, according to Karl Madaras-Kelly, M.D., from the Veterans Administration (VA) Medical Center (Boise, ID, USA).

The finding is important because guidelines for treatment in such cases suggest broad antibiotic therapy with several drugs, followed by modification once a pathogen is identified, Dr. More...
Madaras-Kelly reported her findings at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 2009 in San Francisco, CA, USA. "If you can't identify a pathogen," Dr. Madaras-Kelly said, "you can't really stop [unsuitable] drugs."

The study period--from 2003 through 2008--covers the period before and after the 2005 guidelines were issued by the Infectious Diseases Society of America. The investigators examined records of all patients admitted for pneumonia at six VA medical centers in the northwestern United States, finding 1,568 who met criteria for healthcare-associated pneumonia. Of those, according to Dr. Madaras-Kelly, 92.6% provided one or more cultures, including 81.8% of the total from blood, 49.7% from sputum, and 1.5% from bronchoscopy. However, out of those 1,452 patients with a culture, only 486 (31%) had a pathogen isolated, he noted.

There was no significant year-by-year difference in the proportions with an isolated pathogen, according to Dr. Madaras-Kelly. However, some of the six study sites did better in collecting quality cultures--with result ranges from 6.3-43.6%. The differences were significant at p < 0.001. Dr. Madaras-Kelly noted that clinicians "do adjust treatment when they have a quality culture, but the majority of patients don't have a good culture."

The implications, according to Dr. Madaras-Kelly, include a need to focus on retrieving good quality cultures. "And we also need better methods to diagnose pneumonia because cultures are expensive," he added.

The study's findings have to be interpreted in light of other research suggesting that a pathogen is isolated only 40% of the time in community-acquired pneumonia, according to Lindsay Grayson, M.D., from Austin Hospital (Melbourne, Australia). Dr. Grayson, one of the ICAAC meeting's program cochairs, was not part of the research.

One reason for the failure rate is that patients are frequently given antibiotics before the testing. "[It's] not enough to cure them but enough to confuse the cultures," Dr. Grayson said, and a similar issue may arise with healthcare-associated pneumonia. He stated that the study calls into question "the timing of cultures in relation to any recent antibiotics" and stressed the value of accurate samples.

Related Links:

VA Medical Center


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.